Clinical trial
Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS…
NCT00336557 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT00336557 |
|---|---|
| Title | Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy |
| Official title | A Randomized, Controlled, Open-Label Parallel Group Study to Evaluate the Effect of Regularly Scheduled Neutralizing Antibody Testing on Treatment Patterns Versus Usual Care in High-Dose Interferon Treated Patients |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Multiple Sclerosis |
| Intervention type | Procedure |
| Interventions | NAbs testing |
| Enrollment | 1,230 |
| Start date | Jul 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Jun 13, 2006 |
| Last update posted | Oct 30, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: